| Literature DB >> 28740262 |
Valentina Boeva1,2, Caroline Louis-Brennetot3, Agathe Peltier3, Simon Durand3, Cécile Pierre-Eugène3, Virginie Raynal3,4, Heather C Etchevers5, Sophie Thomas6, Alban Lermine1, Estelle Daudigeos-Dubus7, Birgit Geoerger7, Martin F Orth8, Thomas G P Grünewald8, Elise Diaz9,10, Bertrand Ducos9,10,11, Didier Surdez3, Angel M Carcaboso12, Irina Medvedeva2, Thomas Deller13, Valérie Combaret14, Eve Lapouble15, Gaelle Pierron15, Sandrine Grossetête-Lalami3, Sylvain Baulande4, Gudrun Schleiermacher3,16,17,18, Emmanuel Barillot1, Hermann Rohrer13, Olivier Delattre3,4,18, Isabelle Janoueix-Lerosey3,18.
Abstract
Neuroblastoma is a tumor of the peripheral sympathetic nervous system, derived from multipotent neural crest cells (NCCs). To define core regulatory circuitries (CRCs) controlling the gene expression program of neuroblastoma, we established and analyzed the neuroblastoma super-enhancer landscape. We discovered three types of identity in neuroblastoma cell lines: a sympathetic noradrenergic identity, defined by a CRC module including the PHOX2B, HAND2 and GATA3 transcription factors (TFs); an NCC-like identity, driven by a CRC module containing AP-1 TFs; and a mixed type, further deconvoluted at the single-cell level. Treatment of the mixed type with chemotherapeutic agents resulted in enrichment of NCC-like cells. The noradrenergic module was validated by ChIP-seq. Functional studies demonstrated dependency of neuroblastoma with noradrenergic identity on PHOX2B, evocative of lineage addiction. Most neuroblastoma primary tumors express TFs from the noradrenergic and NCC-like modules. Our data demonstrate a previously unknown aspect of tumor heterogeneity relevant for neuroblastoma treatment strategies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28740262 DOI: 10.1038/ng.3921
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330